February 10, 2024
2 min watch
Save
VIDEO: TearCare improves tear breakup time in patients with dry eye disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Jennifer Loh, MD, explains the results of the SAHARA trial comparing TearCare and Restasis for treating dry eye disease.
The multicenter randomized trial showed both the TearCare system (Sight Sciences) and Restasis (cyclosporine ophthalmic emulsion 0.05%, Allergan) improved tear breakup time and Ocular Surface Disease Index scores after 6 months.
“TearCare did prove better at improving tear breakup time in patients, which makes sense since TearCare is indicated for the treatment of patients with dry eye disease with underlying meibomian gland dysfunction,” Loh said.
Reference:
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Loh reports consulting for Allergan and Sight Sciences.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.